NeoGenomics, Inc. (NEO) 

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeoGenomics, Inc. (“NeoGenomics” or the “Company) (NASDAQ: NEO). Investors who purchased NeoGenomics securities are encouraged to obtain additional information and assist the investigation. 

 

The investigation concerns whether NeoGenomics and certain of its officers and/or directors have violated federal securities laws.

 

On March 28, 2022, NeoGenomics issued a press release announcing that its Chief Executive Officer “will step down as CEO and member of the Board, effective immediately.”   The Company further advised that it “expects revenue for Q1 2022 may be below the low end of its prior guidance of $118 - $120 million and EBITDA for Q1 2022 will be below the low end of its prior guidance of $(15) - $(12) million.”  NeoGenomics also disclosed that “[t]he larger than anticipated EBITDA loss was primarily driven by higher than anticipated Clinical Services cost of goods sold” and that it “has withdrawn its 2022 annual financial guidance issued February 23, 2022.”  On this news, NeoGenomics’ stock price fell $5.30 per share, or 29.79%, to close at $12.49 per share on March 29, 2022.

 

If you are aware of any facts relating to this investigation or purchased NeoGenomics shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.